Letters to the Editor
Recommended Age for Testing for Osteoporosis in Women
FREE PREVIEW Log in or buy this issue to read the full article. AAFP members and paid subscribers get free access to all articles. Subscribe now.
FREE PREVIEW Subscribe or buy this issue. AAFP members and paid subscribers get free access to all articles.
Am Fam Physician. 2010 Feb 1;81(3):252.
Original Article: Alendronate for Fracture Prevention in Postmenopause [Cochrane for Clinicians]
Issue Date: September 1, 2008
Available at: http://www.aafp.org/afp/2008/0901/p579.html
to the editor: The clinical scenario presented in the Cochrane for Clinicians on alendronate (Fosamax) for fracture prevention in postmenopause was not consistent with the U.S. Preventive Services Task Force (USPSTF) recommendations. The patient in the clinical scenario was a 55-year-old woman with no history of a fracture and no other risk factors for osteoporosis. The USPSTF does not recommend testing women of this age for osteoporosis. The earliest age group in which they recommend testing is 60 to 64 years, and only if the patient is at increased risk for osteoporotic fractures.1 The USPSTF concluded that the balance of benefits and harms from screening and treatment was too close to make a general recommendation for this age group. Otherwise, they recommend routine screening once after age 65 years for all women.
The most significant risk factor for a fracture is olderage. The authors noted that alendronate was more effective with increasing age. Once bisphosphonate treatment is initiated, it may need to be continued for the remainder of the patient's life. Therefore, the decision to initiate pharmacologic therapy for women younger than 65 years should be based on more than the results of a dual-energy x-ray absorptiometry (DEXA) scan. Recently, an absolute fracture prediction algorithm (FRAX) was developed to identify patients at high risk of a fracture and for whom treatment would likely be beneficial.2 However, for patients older than 65 years, the use of the T-score alone yields similar recommendations.3
Fracture prevention begins soon after the start of bisphosphonate therapy and before there has been a significant increase in the bone mineral density.4 So, physicians should wait to test and treat patients until the benefit is significantly greater than the risk. I would have preferred the patient in the clinical scenario to be older than 60 years to reinforce the concept of waiting to test for osteoporosis until the age at which pharmacologic treatment is more likely to be beneficial.
Author disclosure: Nothing to disclose.
1. Nelson HD, Helfand M, Woolf SH, Allan JD. Screening for postmenopausal osteoporosis: a review of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2002;137(6):529–541.
2. Kanis JA, Johnell O, Oden A, Johansson H, McCloskey E. FRAX and the assessment of fracture probability in men and women from the UK. Osteoporosis Int. 2008;19(4):385–397.
3. Dawson-Hughes B, Tosteson AN, Melton LJ III, et al., for the National Osteoporosis Foundation Guide Committee. Implications of absolute fracture risk assessment for osteoporosis practice guidelines in the USA. Osteoporosis Int. 2008;19(4):449–458.
4. Cummings SR, Karpf DB, Harris F, et al. Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. Am J Med. 2002;112(4):281–289.
editor's note: This letter was sent to the authors of “Alendronate for Fracture Prevention in Postmenopause,” who declined to reply.
Send letters to Kenneth W. Lin, MD, MPH, Associate Deputy Editor for AFP Online, e-mail: email@example.com, or 11400 Tomahawk Creek Pkwy., Leawood, KS 66211-2680.
Please include your complete address, e-mail address, and telephone number. Letters should be fewer than 400 words and limited to six references, one table or figure, and three authors.
Letters submitted for publication in AFP must not be submitted to any other publication. Possible conflicts of interest must be disclosed at time of submission. Submission of a letter will be construed as granting the American Academy of Family Physicians permission to publish the letter in any of its publications in any form. The editors may edit letters to meet style and space requirements.
Copyright © 2010 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact firstname.lastname@example.org for copyright questions and/or permission requests.
Want to use this article elsewhere? Get Permissions